Details of the Drug Formulations

General Information of Drug (ID: DM7Q98D)

Drug Name
Ruxolitinib Drug Info
Synonyms Ruxolitinib (JAK inhibitor)
Indication
Disease Entry ICD 11 Status REF
Essential thrombocythemia 3B63.1Z Approved [1]
High-risk myelofibrosis 2A20.2 Approved [2]
Myelofibrosis 2A22 Approved [3]
Myeloproliferative neoplasm 2A20 Approved [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [5]
Pancreatic cancer 2C10 Phase 3 [2]
Atopic dermatitis EA80 Phase 1/2 [6]
Vitiligo ED63.0 Phase 1/2 [6]
Cross-matching ID
PubChem CID
25126798
ChEBI ID
CHEBI:66919
CAS Number
941678-49-5
TTD ID
D04LKS
ACDINA ID
D00611

Full List of Drug Formulations Containing This Drug

Ruxolitinib Phosphate eq 5mg base tablet
Company Formulation ID FDA Description
yte Corp F23988 Microcrystalline Cellulose; Lactose Monohydrate; Magnesium Stearate; Colloidal Silicon Dioxide; Sodium Starch Glycolate; Povidone; Hydroxypropyl Cellulose
------------------------------------------------------------------------------------
Ruxolitinib Phosphate eq 10mg base tablet
Company Formulation ID FDA Description
yte Corp F23989 Microcrystalline Cellulose; Lactose Monohydrate; Magnesium Stearate; Colloidal Silicon Dioxide; Sodium Starch Glycolate; Povidone; Hydroxypropyl Cellulose
------------------------------------------------------------------------------------
Ruxolitinib Phosphate eq 15mg base tablet
Company Formulation ID FDA Description
yte Corp F23990 Microcrystalline Cellulose; Lactose Monohydrate; Magnesium Stearate; Colloidal Silicon Dioxide; Sodium Starch Glycolate; Povidone; Hydroxypropyl Cellulose
------------------------------------------------------------------------------------
Ruxolitinib Phosphate eq 20mg base tablet
Company Formulation ID FDA Description
yte Corp F23991 Microcrystalline Cellulose; Lactose Monohydrate; Magnesium Stearate; Colloidal Silicon Dioxide; Sodium Starch Glycolate; Povidone; Hydroxypropyl Cellulose
------------------------------------------------------------------------------------
Ruxolitinib Phosphate eq 25mg base tablet
Company Formulation ID FDA Description
yte Corp F23992 Microcrystalline Cellulose; Lactose Monohydrate; Magnesium Stearate; Colloidal Silicon Dioxide; Sodium Starch Glycolate; Povidone; Hydroxypropyl Cellulose
------------------------------------------------------------------------------------
Ruxolitinib 10 mg tablet
Company Formulation ID FDA Description
Incyte Corporation F19707 Lactose monohydrate; Magnesium stearate; Povidone; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type e); Sodium starch glycolate type a potato
------------------------------------------------------------------------------------
Ruxolitinib 15 mg tablet
Company Formulation ID FDA Description
Incyte Corporation F19708 Lactose monohydrate; Magnesium stearate; Povidone; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type e); Sodium starch glycolate type a potato
------------------------------------------------------------------------------------
Ruxolitinib 20 mg tablet
Company Formulation ID FDA Description
Incyte Corporation F19709 Lactose monohydrate; Magnesium stearate; Povidone; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type e); Sodium starch glycolate type a potato
------------------------------------------------------------------------------------
Ruxolitinib 25 mg tablet
Company Formulation ID FDA Description
Incyte Corporation F19710 Lactose monohydrate; Magnesium stearate; Povidone; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type e); Sodium starch glycolate type a potato
------------------------------------------------------------------------------------
Ruxolitinib 5 mg tablet
Company Formulation ID FDA Description
Incyte Corporation F19711 Lactose monohydrate; Magnesium stearate; Povidone; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type e); Sodium starch glycolate type a potato
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Ruxolitinib FDA Label
5 Incyte begins Phase III trial of ruxolitinib to treat Covid-19. 20.April.2020.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)